Doctor's Bio
Dr. Kelley is a faculty member in the Division of Infectious Diseases at Emory University with a secondary appointment in the Department of Epidemiology, Rollins School of Public Health. She graduated from Emory University with an MD/MPH degree and completed her Internal Medicine residency at the University of California, San Francisco, and her infectious diseases fellowship at Emory University.
Dr. Colleen F. Kelley has a multidisciplinary background and previous clinical and research experience in HIV medicine, HIV epidemiology, clinical outcomes research, and laboratory-based HIV research. She sees outpatients at Grady’s Ponce de Leon Center and inpatients on the Infectious Diseases consult service and Special Immunology Service at Grady Hospital.
The current focus of her research is on biomedical HIV prevention interventions, including pre- and post-exposure prophylaxis (PrEP and PEP) and HIV vaccines. She conducts translational immunology studies of HIV susceptibility in men who have sex with men (MSM) to better understand rectal HIV transmission. Dr. Kelley is a site investigator for the HIV Vaccine Trials Network at the Hope Clinic and also collaborates closely with colleagues in the School of Public Health on several HIV prevention studies, including PrEP implementation projects.
Board Certifications
American Board of Internal Medicine
Affiliations
Emory
Education & Training
- Medical School: Emory University School of Medicine
- Residency: University of California San Francisco, School of Medicine
Fellowships
Emory University School of Medicine
Awards and Honors
- 2021: HIV Medicine Association National Research Award
- 2020: Emory Department of Medicine Shanthi Sitaraman Silver Pear Mentoring Award
- 2019: Clinical Track Rapporteur. 2019 IAS Conference on HIV Science. Mexico City
- 2019: Shanta M. Zimmer Mentoring Award, Division of Infectious Diseases, Emory University
- 2019: Official IDSA/HIVMA spokesperson
- 2018: Chair, National CFAR Science Symposium
- 2015: Junior Investigator presentation, Nation CFAR Scientific Symposium, November 2015
- 2015-2018: Infectious Disease Society of America Education Committee, HIVMA representative
- 2015: President’s Emergency Plan for AIDS Relief (PEPFAR) Pre-exposure Prophylaxis (PrEP) Expert Working Group
- 2015: HIV Vaccine Trials Network 803/HIV Prevention Trials Network Pre-exposure Prophylaxis (PrEP) Americas Working Group, 2015-present
- 2014: National Institutes of Health, Early Career Reviewer member
Locations and Directions
Ponce De Leon Center
Phone: (404) 616-2440
Location:
341 Ponce De Leon Ave. NE
Atlanta, GA 30308
Publications
- Mpox-specific cellular and humoral immunity in mpox survivors living with HIV.
Stampfer SD, Priyamvada L, Sambyal S, Gangadhara S, Moriarty M, Satheshkumar PS, Grifoni A, Sette A, Sheth AN, Kelley CF, Amara RR
Cell reports. 2025;44(11):116501.
PMID: 41176764 - Persistence is Resistance: The fight to End the HIV Epidemic Hangs in the Balance.
Kelley CF, Weddle A, Agwu A, Bolduc PJ, Person AK
The Journal of infectious diseases. 2025;
PMID: 40717538 - Lenacapavir: a potential game changer for HIV prevention in the Americas, if the game is played equitably.
Cantos VD, Ramírez BC, Kelley CF, Rio CD, Grinsztejn B
Lancet regional health. Americas. 2025;
PMID: 40546885 - Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study.
Huang Y, Zhang L, Gelderblom H, Seaton KE, Yates NL, Paez CA, Karuna ST, Andrew P, Gamble T, Robinson ST, Ledgerwood JE, Hyrien O, Walsh SR, Gay CL, Gwira JA, Spiegel HML, Sobieszczyk ME, Mannheimer SB, Edupuganti S, Hurt CB, Stephenson KE, Yu C, Kelley CF, Mahomed S, Siegel M, Yacovone M, Pensiero MN, Donnell D, Cohen MS, Corey L, Gilbert PB, Koup RA, Tomaras GD,
EBioMedicine. 2025;
PMID: 40516378 - Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial.
Seaton KE, Paez CA, Yu C, Karuna ST, Gamble T, Miner MD, Heptinstall J, Zhang L, Gao F, Yacovone M, Spiegel H, Dumond JB, Anderson M, Piwowar-Manning E, Dye B, Tindale I, Proulx-Burns L, Trahey M, Takuva S, Takalani A, Bailey VC, Kalams SA, Scott H, Mkhize NN, Weiner JA, Ackerman ME, McElrath MJ, Pensiero M, Barouch DH, Montefiori D, Tomaras GD, Corey L, Cohen MS, Huang Y, Mahomed S, Siegel M, Kelley CF,
The lancet. HIV. 2025;12(6):e405-e415.
PMID: 40441807 - Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials.
Andrews LIB, Halloran ME, Neuzil KM, van der Laan L, Huang Y, Andriesen J, Patel M, Fisher LH, Janes H, Rouphael N, Walsh SR, Theodore DA, Tieu HV, Sobieszczyk M, El Sahly HM, Baden LR, Falsey AR, Campbell TB, Kelley CF, Healy CM, Immergluck L, Luft B, Hirsch I, de Bruyn G, Truyers C, Priddy F, Sumner KM, Flannery B, Follmann D, Gilbert PB,
JAMA network open. 2025;8(5):e2512763.
PMID: 40434773 - Preventing Premature Pre-Exposure Prophylaxis Discontinuation and Sexually Transmitted Infections Among Men Who Have Sex With Men (Project PEACH): Protocol for a Prospective Cohort Study.
Aldredge A, Carter D, DeCree CA, Gardner EV, Herring GB, Kaabi O, Moges-Banks R, Valencia R, Kelley CF, Sullivan PS
JMIR research protocols. 2025;
PMID: 40267471 - Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.
Marcus JL, Weddle A, Kelley CF, Agwu A, Montalvo S, Sherman E, Vijayan T, Gutierrez J, Hickey MD, Dilworth SE, Krakower D, Davis TL, Collins LF, McNulty MC, Colasanti JA, Christopoulos KA
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025;
PMID: 39873495 - Rectal mucosal inflammation, microbiome, and wound healing in men who have sex with men who engage in receptive anal intercourse.
Van Doren VE, Ackerley CG, Arthur RA, Murray PM, Smith SA, Hu YJ, Kelley CF
Scientific reports. 2024;14(1):31598.
PMID: 39738273 - Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial.
Follmann D, Wang X, Baden LR, El Sahly HM, Essink B, Gilbert P, Janes HE, Kelley CF, Berman MA, Frank I, Chu E, Deng W, Priddy F, Dixit A, Tomassini JE, Das R, Miller J, Zhou H
Open forum infectious diseases. 2024;11(12):ofae689.
PMID: 39679349
PLANNING
PREPARING FOR YOUR VISIT
Whether you’re a patient or you’re visiting one, a little planning beforehand can make your visit to Grady easier and more comfortable. Here, you’ll find everything you need to prepare for your visit, including an appointment checklist, admissions information, dining options, and much more.